Eryptosis, the suicidal erythrocyte death, leads to cell shrinkage and cell membrane scrambling with phosphatidylserine exposure at the cell surface. Eryptotic erythrocytes adhere to the vascular wall by binding of phosphatidylserine to the CXC chemokine ligand 16 (CXCL16). Stimulators of eryptosis include increased cytosolic Ca 2ϩ activity, energy depletion, and activation of ceramide-producing sphingomyelinase. The present study explored whether sphingomyelinase triggers erythrocyte adhesion to endothelial cells. To this end, human erythrocytes were exposed for 6 h to bacterial sphingomyelinase (1-10 mU/ml) and phosphatidylserine exposure was estimated from fluorescent annexin-V-binding, cell volume from forward scatter in FACS-analysis, erythrocyte adhesion to human umbilical vein endothelial cells (HUVEC) from trapping of labeled erythrocytes in a flow chamber under flow conditions at arterial shear rates, and CXCL16 protein abundance utilizing Western blotting and FACS analysis of fluorescent antibody binding. As a result, sphingomyelinase (Ն1 mU/ml) triggered cell shrinkage, phosphatidylserine exposure and erythrocyte adhesion to HUVEC, effects blunted by Ca 2ϩ removal. Adhesion was significantly blunted by phosphatidylserine-coating annexin-V (5 l/ml), following addition of neutralizing antibodies against endothelial CXCL16 (4 g/ml) and following silencing of the CXCL16 gene with small interfering RNA. Pretreatment of HUVEC with sphingomyelinase upregulated CXCL16 protein abundance. Six hours pretreatment of HUVEC with sphingomyelinase (10 mU/ml) or C6-ceramide (50 M) augmented erythrocyte adhesion following a 30-min treatment with Ca 2ϩ ionophore ionomycin (1 M) or following energy depletion by 48-h glucose removal. Thus exposure to sphingomyelinase or C6-ceramide triggers eryptosis followed by phosphatidylserine-and CXCL16-sensitive adhesion of eryptotic erythrocytes to HUVEC.
eryptosis; phosphatidylserine; CXCL16; adhesion; endothelium THE SUICIDAL ERYTHROCYTE DEATH or eryptosis is characterized by cell shrinkage and cell membrane scrambling with exposure of phosphatidylserine at the erythrocyte surface (29) . Eryptosis may be triggered by activation of Ca 2ϩ -permeable cation channels leading to increase of cytosolic Ca 2ϩ concentration (29) . Increased cytosolic Ca 2ϩ activates Ca 2ϩ -sensitive K ϩ channels (29) resulting in subsequent exit of KCl with osmotically obliged water and thus in cell shrinkage (29) . Increased cytosolic Ca 2ϩ further triggers phospholipid scrambling of the cell membrane (29) . The sensitivity of erythrocytes to the scrambling effect of Ca 2ϩ may be enhanced by ceramide (28; 30) , which may be generated by sphingomyelinase (33) .
Eryptosis contributes to the pathophysiology of several diseases (29) , such as diabetes mellitus, renal insufficiency, iron deficiency, phosphate depletion, hemolytic uremic syndrome, sepsis, sickle cell disease, malaria, Wilson's disease, and presumably metabolic syndrome (7, 16, 29, 32, 49, 59) . Ceramide formation significantly contributes to the stimulation of eryptosis in several of those diseases including hemolytic uremic syndrome, sepsis, fever, and Wilson disease (16, 29) . Moreover, ceramide-dependent and -independent eryptosis is triggered by a wide variety of small molecules (4 -7, 14, 15, 18, 19, 27, 29, 41, 44, 45, 49) .
Phosphatidylerine-exposing cells may activate coagulant enzymes (12) and adhere to the vascular wall (11) , thus triggering thrombosis and thrombo-occlusive diseases (2, 12, 13, 17, 43, 55, 60) . However, the mechanisms possibly underlying erythrocyte-endothelial cell interaction, especially in diseases with excessive eryptosis, are not well defined.
The adhesion of phosphatidylserine-exposing erythrocytes to endothelial cells involves the transmembrane CXC chemokine ligand 16 (CXCL16; Ref. 11), a scavenger receptor binding phosphatidylserine and oxidized low-density lipoprotein (20, 48) . CXCL16 is expressed at the surface of inflammatory cells (39) . Binding to CXCL16 fosters internalization of the bound particles (20) .
The present study explored whether exposure of erythrocytes to sphingomyelinase results in adherence to human umbilical vein endothelial cells (HUVEC) under flow conditions and, if so, whether the adherence is blunted by coating the phosphatidylserine at the surface of eryptotic erythrocytes with annexin-V or by coating endothelial CXCL16 with neutralizing antibodies.
MATERIALS AND METHODS
Erythrocytes, solutions, and chemicals. Leukocyte-depleted erythrocytes were kindly provided by the blood bank of the University of Tuebingen. Viability of erythrocytes may depend on the donor and the storage time thus causing some interindividual variability. To avoid any bias potentially introduced by the use of different erythrocyte batches, comparisons were always made within a given erythrocyte batch. The study was approved by the Ethics Committee of the Eberhard Karls University of Tuebingen.
Erythrocytes were incubated in vitro at a hematocrit of 0.4% in Ringer solution containing the following (in mM): 125 NaCl, 5 KCl, 1 MgSO 4, 32 HEPES, 5 glucose, and 1 CaCl2, pH 7.4 at 37°C. Where indicated, 0.01 U/ml bacterial sphingomyelinase (Sigma) was added, glucose removed (replaced by mannitol), cytosolic Ca 2ϩ concentration increased by exposure to 1 M Ca 2ϩ ionophore ionomycin (Sigma, Taufkirchen, Germany), Ca 2ϩ replaced by EGTA, annexin-V (1:200 dilution, Roche) added to coat and thereby functionally neutralize phosphatidylserine at the surface of eryptotic erythrocytes, or anti-CXCL16 antibody (4 g/ml, R&D Systems) added 2 h before perfusion experiments to neutralize endothelial CXCL16.
Cell culture and silencing of HUVEC. HUVEC from early passage of culture were grown to confluency in complete endothelial cell basal medium (PAA) containing growth factors and 10% FBS.
For silencing CXCL16, HUVEC were cultured on six-well plates (2.5 ϫ 10 5 cells). The cells were subsequently transfected with 10 nM validated small interfering (si)RNA for CXCL16 (ID no. s33807; Ambion) or with 10 nM negative control siRNA (ID no. 4390843; Ambion) using siPORT amine transfection agent (Ambion) according to the manufacturer's protocol. The cells were used 48 h after transfection.
FACS analysis. For determination of annexin V-binding and forward scatter, the cells were incubated under the respective experimental conditions, and a 50-l cell suspension was washed in Ringer solution containing 5 mM CaCl 2 and then stained for 20 min with annexin-V-Fluos (1:500 dilution; Roche) under protection from light (51) . In the following, the forward scatter of the cells was determined and annexin-V fluorescence intensity was measured in FL-1 with an excitation wavelength of 488 nm and an emission wavelength of 530 nm on a FACS-Calibur (BD Biosciences).
For determination of CXCL16 abundance at the surface utilizing anti-human CXCL16-phycoerythrin, HUVEC were incubated 6 h at 37°C, 5% CO 2 with or without 0.01 U/ml sphingomyelinase. The cells were washed three times in isotonic phosphate buffer PBS (supplemented with 0.5% BSA) by centrifugation at 1,600 g for 5 min to remove any residual growth factors that may be present in the culture medium. Cells were then resupended in the same buffer at a final concentration of 4ϫ10 6 cells/ml. A volume of 25 l of cells (1ϫ10 5 ) was transferred to 5 ml tube for staining. A volume of 10 l of PE-conjugated anti-CXCL16 antibody (R&D Systems) was added and incubated for 45 min at 2-8°C. Following incubation, unreacted anti-CXCL16 reagent was removed by washing the cells twice in 4 ml of same PBS buffer and resuspending in 200 l of PBS buffer for final flow cytometric analysis.
Determination of ceramide formation. For the determination of ceramide, a monoclonal antibody-based assay was used. After incubation with and without 10 mU/ml sphingomyelinase for 6 h, cells were stained for 1 h at 37°C with 1 g/ml anti-ceramide antibody (clone MID 15B4; Alexis, Grünberg, Germany) in PBS containing 0.1% BSA at a dilution of 1:5. The samples were washed twice with PBS-BSA. Subsequently, the cells were stained for 30 min with polyclonal FITC-conjugated goat anti-mouse IgG-and IgMspecific antibody (Pharmingen, Hamburg, Germany) diluted 1:50 in PBS-BSA. Unbound secondary antibody was removed by repeated washing with PBS-BSA. The samples were then analyzed by flow cytometric analysis in FL-1.
Dynamic erythrocyte adhesion to endothelium in vitro. Cultured HUVEC (5 ϫ 10 5 ) were attached on sterile coverslips coated with 0.2% gelatine (Sigma-Aldrich) by overnight incubation in complete endothelial cell basal medium under cell culture conditions for 24 h. Erythrocytes prepared as indicated were perfused on a HUVEC monolayer in a flow chamber model (Harvard) at arterial shear rates (1, 200 Ϫs ). The interaction events were recorded with a CCD camera (Carl Zeiss) with ϫ20 magnification, followed by analysis of the number adherent erythrocytes per high powerfield.
Western blot analysis. HUVEC were lysed with ice cold RIPA lysis buffer (Cell Signaling, Danvers, MA) supplemented with complete protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific, Rockford, IL). After centrifugation at 10,000 rpm for 5 min, 60 g of proteins were boiled in nonreducing protein loading buffer (Thermo Fisher Scientific) at 100°C for 10 min. Proteins were separated on SDS-polyacrylamide gels and transferred to PVDF membranes. The membranes were incubated overnight at 4°C with rat anti-CXCL16 antibody (diluted 1:500; R&D Systems, Wiesbaden-Nordenstadt, Germany) or rabbit anti-GAPDH antibody (diluted 1:1,000; Cell Signaling) and then with secondary anti-rat horseradish peroxidase-conjugated antibody (diluted 1:1,000; Cell Signaling) or secondary antirabbit horseradish peroxidase-conjugated antibody (diluted 1:1,000;
Cell Signaling) for 1 h at room temperature. For loading controls, the membranes were stripped in stripping buffer (Carl Roth, Karlsruhe, Germany) at 56°C for 5 min. Antibody binding was detected with the SuperSignal ELISA Femto Maximum Sensitivity Substrate (Pierce, Rockford, IL), and bands were quantified using Quantity One Software (Bio-Rad, München, Germany).
Quantitative real-time PCR. Gene expression and silencing efficiency of CXCL16 in HUVEC was verified by quantitative real-time PCR (RT-PCR). To this end, total RNA was isolated using the Trifast Reagent (Peqlab). Reverse transcription of 2 g RNA was performed using oligo(dT) [12] [13] [14] [15] [16] [17] [18] 2% agarose gel electrophoresis. All PCRs were performed in duplicate, and mRNA fold changes were calculated by the 2 Ϫ⌬⌬CT method using GAPDH as internal reference.
Statistics. Data are expressed as arithmetic means Ϯ SE. Statistical analysis was made using t-test or paired ANOVA with Tukey's test as posttest, as appropriate; n denotes the number of different erythrocyte specimens studied. The batches of erythrocytes differed moderately in their susceptibility to eryptosis. Thus the control values were not identical in all series of experiments. To avoid any bias potentially introduced by the use of different erythrocyte batches, comparison was always made within a given erythrocyte batch.
RESULTS
Effect of sphingomyelinase treatment on erythrocyte forward scatter and cell membrane scrambling. FACS analysis was performed to elucidate the effect of bacterial sphingomyelinase on human erythrocytes. As illustrated in Fig. 1, A and B, exposure to bacterial sphingomyelinase (Ն1 mU/ml) was followed by decrease of forward scatter reflecting cell shrinkage. The cell shrinkage was partially dependent on the presence of Ca 2ϩ and was thus significantly blunted in the nominal absence of Ca 2ϩ (Fig. 1, C and D) .
Sphingomyelinase further stimulated cell membrane scrambling with phosphatidylserine exposure at the cell surface. As illustrated in Fig. 2, A and B, sphingomyelinase (Ն1 mU/ml) treatment was followed by a significant increase of the percentage of annexin-V binding erythrocytes pointing to the appearance of erythrocytes exposing phosphatidylserine at their surface. The phosphatidylserine exposure was abrogated in the nominal absence of Ca 2ϩ , and thus phosphatidylserine exposure was dependent on the presence of Ca 2ϩ (Fig. 2, C and D) . Effect of sphingomyelinase treatment on erythrocyte adhesion. Phosphatidylserine-exposing erythrocytes might adhere to the vascular wall. To test this possibility, the effect of sphingomyelinase on adherence of erythrocytes to HUVEC was determined under in vitro flow conditions at arterial shear rates of 1,200
Ϫs . As illustrated in Fig. 3A , treatment of erythrocytes with sphingomyelinase (10 mU/ml) was followed by marked increase of the percentage of erythrocytes adhering to HUVEC.
Additional experiments were performed to investigate whether enhanced vascular adhesion of sphingomyelinasetreated erythrocytes requires phosphatidylserine exposure at the cell surface. To this end, phosphatidylserine at the erythrocyte surface was coated with annexin-V, which firmly binds to and thus masks phosphatidylserine. As illustrated in Fig. 3B , the increased adhesion of sphingomyelinase-treated erythrocytes to HUVEC under flow at shear rates of 1, 200 Ϫs was significantly attenuated in the presence of annexin-V (1:200 dilution).
Since CXCL16 has been shown to bind phosphatidylserine and to be involved in cell adhesion processes (11, 20, 48) , further experiments were performed to test whether the binding of sphingomyelinase-treated erythrocytes to endothelium under flow conditions involves CXCL16. To this end, HUVEC were exposed to an antibody directed against CXCL16 (4 g/ml). As shown in Fig. 3C , the adhesion to endothelium of sphingomyelinase-treated erythrocytes was significantly decreased following exposure of HUVEC cells to CXCL16-blocking antibody compared with treatment with isotype control antibody of the same concentration.
To further test for a role of CXCL16 in adhesion of eryptotic erythrocytes to endothelial cells, endothelial CXCL16 expression was decreased by transfection of HUVEC with CXCL16 siRNA. As shown in Fig. 3D , CXCL16 silencing significantly decreased the adhesion of ionomycin-treated phosphatidylserine-exposing erythrocytes to endothelial cells at arterial shear rates compared with endothelium transfected with negative control siRNA of the same concentration.
Effect of sphingomyelinase treatment on endothelial CXCL16 expression and ceramide production. According to the experiments presented thus far, spingomyelinase exposure fosters erythrocyte adhesion to endothelial cells by triggering eryptosis. At least in theory, sphingomyelinase could be additionally effective by modifying CXCL16 expression in endothelial cells. To explore that possibility, HUVEC were incubated for 6 h without or with sphingomyelinase (1, 5, and 10 mU/ml) and CXCL16 protein abundance was determined by both Western blotting and FACS analysis. As illustrated in Fig. 4 , A-C, the exposure of HUVEC to sphingomyelinase was followed by a significant increase of CXCL16 protein abundance. Figure  4D illustrates the formation of ceramide in response to sphingomyelinase (10 mU/ml) in HUVEC after 6 h of stimulation.
To check the transcript levels of CXCL-16 in HUVEC cells, RT-PCR was performed on mRNA of HUVEC without treatment or following treatment with 100 mU/ml sphingomyelinase. The CXCL-16 mRNA abundance was not significantly different (P ϭ 0.63) between untreated (1.01 Ϯ 0.05) and sphingomyelinase-treated (0.95 Ϯ 0.11) HUVEC. Erythrocyte adhesion following sphingomyelinase treatment of HUVEC. Additional experiments were performed to elucidate whether the enhanced expression of CXCL16 in sphingomyelinase-treated endothelial cells influenced the adhesion of phosphatidylserine exposing erythrocytes. To this end, eryptosis was induced by a 30-min treatment of erythrocytes with the Ca 2ϩ ionophore ionomycin (1 M) and endothelial adhesion was tested utilizing HUVEC, which were either left untreated or were treated for 6 h with sphingomyelinase (10 mU/ml). As illustrated in Fig. 5A , the treatment with ionomycin was followed by a marked increase of erythrocyte adhesion to HUVEC. The additional treatment of HUVEC with sphingomyelinase was followed by a further significant increase of erythrocyte adhesion to the endothelial cells.
In an additional series of experiments, eryptosis was induced by glucose deprivation of erythrocytes for 48 h. Again, endothelial adhesion was tested utilizing HUVEC, which were either left untreated or were treated for 6 h with sphingomyelinase (10 mU/ml). Glucose deprivation was followed by a marked increase of erythrocyte adhesion to HUVEC. The additional treatment of HUVEC with sphingomyelinase was again followed by a further significant increase of erythrocyte adhesion to the endothelial cells (Fig. 5B) .
Effect of C6-ceramide treatment on adhesion of erythrocytes to HUVEC cells. In a final series of experiments, the effect of C6-ceramide on eryptosis and erythrocyte adhesion to HUVEC was explored. As illustrated in Fig. 6A , a 6-h treatment with C6-ceramide (50 M) was followed by a significant increase of the percentage of annexin-V binding erythrocytes pointing to the appearance of erythrocytes exposing phosphatidylserine at their surface. The phosphatidylserine exposure was significantly reduced in the nominal absence of Ca 2ϩ . C6-ceramide further fostered the adhesion of erythrocytes to HUVEC under in vitro flow conditions at arterial shear rates of 1,200
Ϫs . As illustrated in Fig. 6B , treatment of erythrocytes with C6-ceramide (50 M) was followed by marked increase of the percentage of erythrocytes adhering to HUVEC.
Additional experiments were performed to elucidate whether the enhanced expression of CXCL16 in C6-ceramide-treated endothelial cells influenced the adhesion of phosphatidylserine exposing erythrocytes. To this end, eryptosis was induced by a 30-min treatment of erythrocytes with the Ca 2ϩ ionophore ionomycin (1 M) and endothelial adhesion was tested utilizing HUVEC that were either left untreated or were treated for 6 h with C6-ceramide (50 M). As illustrated in Fig. 6C , the treatment with ionomycin was followed by a marked increase of erythrocyte adhesion to HUVEC.
In an additional series of experiments, eryptosis was induced by glucose deprivation of erythrocytes for 48 h. Again, endothelial adhesion was tested utilizing HUVEC that were either left untreated or were treated for 6 h with C6-ceramide (50 M). Glucose deprivation was followed by a marked increase of erythrocyte adhesion to HUVEC (Fig. 6D) .
DISCUSSION
The present observations confirm previous studies (29) demonstrating that exposure of erythrocytes to sphingomyelinase leads to cell shrinkage and cell membrane scrambling, both hallmarks of suicidal erythrocyte death or eryptosis. The present observations further reveal that exposure to sphingomyelinase is followed by phosphatidylserine-and SR-PSOX/ CXCL16-dependent binding of affected erythrocytes to endothelial cells.
The effect of sphingomyelinase on both eryptosis and adhesion to endothelial cells is dependent on the presence of Ca 2ϩ . As shown earlier (29) , ceramide sensitizes the erythrocytes to the effects of Ca 2ϩ . An increase of cytosolic Ca 2ϩ activity stimulates erythrocyte cell membrane scrambling leading to phosphatidylserine exposure at the cell surface (29) . An increase of cytosolic Ca 2ϩ activity further activates Ca 2ϩ -sensitive K ϩ channels (29) with subsequent exit of K ϩ , hyperpo- larization of the cell membrane, exit of Cl Ϫ , and thus cellular loss of KCl together with osmotically obliged water, effects eventually leading to cell shrinkage (29) . Sphingomyelinase is primarily effective by increasing Ca 2ϩ sensitivity of the erythrocyte (29). Eryptosis is followed by adhesion of the eryptotic erythrocytes to endothelial cells. Erythrocyte membrane proteins are known to participate in the pathophysiology of thrombosis, which may involve increased adhesion of erythrocytes to endothelial cells (2) . The adhesion is expected to interfere with microcirculation, which presumably contributes to cardiovascular complications in several diseases such as diabetes or chronic renal failure (10, 37, 42) .
As reported earlier (11), eryptotic erythrocytes bind at least partially to CXCL16 or SR-PSOX, a scavenger receptor binding phosphatidylserine and oxidized low-density lipoprotein (24) . CXCL16 is produced by several cell types including dendritic cells (21) , lymphocytes (56), vascular smooth muscle cells (52), bone marrow stromal cells (40) , tumor cells (35, 36) , and cardiac tissue (58) . SR-PSOX/CXCL16 expression in endothelial cells is upregulated by proinflammatory cytokines, such as TNF-␣ or IFN-␥ (1, 25) , known mediators of inflammation and ischemia (46, 50) . TNF␣ stimulates CXCL16 production via a signaling cascade involving NF-B, p38 MAPK, and protein kinase A (22) . We show here that CXCL16 expression is further upregulated by exposure of endothelial cells to sphingomyelinase.
Endothelial CXCL16 mediates not only adhesion of erythrocytes but also adhesion of leukocytes (25, 47) . CXCL16 promotes the adhesion of monocytes to the endothelium during atherogenesis (24) . CXCL16 is further expressed in macrophages of atherosclerotic plaques (39) and presumably contributes to thrombotic vascular complications. Future studies will be needed to clarify whether the expression of CXCL16 in leukocytes is similarly regulated by sphingomyelinase. Adhesion of eryptotic erythrocytes to phagocytosing cells fosters phagocytosis and thus clearance from circulating blood (29) . The phagocytosis could be suppressed by coating of eryptotic erythrocytes with annexin-V (32).
The HUVEC utilized in the present study express several adhesion molecules including integrins ␣ v (e.g., ␣ v ␤ 3 , or ␣ v ␤ 5 ) and ␤ 1 , E-and P-selectins, laminin ␣ 5 , vWF, and the adhesion molecules ICAM-1, PECAM-1, or VCAM-1 (3, 8) and are thus widely used as model cells for adhesion to the vascular wall (3, 8, 9, 54) . Similar to what was shown in earlier studies (57) blocking phosphatidylserines or neutralizing CXCL16 by antibodies decreased but did not fully abrogate adhesion. Thus, binding of eryptotic erythrocytes to the vascular wall may involve further mechanisms. Phosphatidylserines could interact with subendothelial thrombospondin (53) or endothelial CD36 (38) , and erythrocytes may express further molecules participating in erythrocyte adhesion to HUVEC, such as ICAM-4 adhering to endothelial ␣ v ␤ 3 integrins (23) or the erythrocyte Lutheran blood group/basal cell adhesion molecule (Lu/BCAM) binding to endothelial cell laminin ␣ 5 (54) .
The present observations strongly suggest that acid sphingomyelinase stimulates eryptosis with cell membrane scrambling leading to adhesion of externalized phosphatidylserine to endothelial CXCL16. It should be pointed out, however, that those observations do not rule out further mechanisms involved in the stimulation of erythrocyte adhesion by acid sphingomyelinase operative in addition to phosphatidylserine and CXCL-16. Clearly, additional experimentation is required to fully unravel the complex machinery underlying erythrocyte adhesion to the vascular wall.
In conclusion, the present observations show that treatment of erythrocytes with sphingomyelinase is followed by triggering of eryptosis with partially phosphatidylserine-and CXCL16-dependent binding of the eryptotic erythrocytes to the vascular wall. Sphingomyelinase-dependent eryptosis with subsequent adhesion of erythrocytes to the vascular wall may contribute to the pathophysiology of several diseases involving ceramide formation including hemolytic uremic syndrome (31), sepsis (26) , fever (16) , and Wilson disease (34) .
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